Apixaban is jointly commercialized by Pfizer IncPFE and Bristol Myers Squibb CoBMY.
Researchers also found that a small number of cases caused serious harm.
Around 29.1% of people given the drug ended up back in the hospital or died, compared with 30.8% receiving standard care.
The 402-subject study showed no benefit from Apixaban regarding the number of days patients remained alive and out of the hospital 60 days after their initial discharge.
The study will continue to test another drug called Atorvastatin, a widely used lipid-lowering drug, or “statin,” that acts on other mechanisms of disease that are thought to be important in COVID.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
